Resistance to MAPK Pathway Inhibition in <i>BRAF</i>-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors

Resistance to MAPK Pathway Inhibition in <i>BRAF</i>-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors

The current treatment for refractory <i>BRAF</i>-V600E mutant metastatic colorectal cancer (mCRC) involves combined inhibition of BRAF and the epidermal growth factor receptor (EGFR). However, tumour responses are often short-lived due to a rebound in mitogen-activated protein kinase (MA...

Full description

Saved in:
Bibliographic Details
Main Authors: Layla El Bouazzaoui, Daniëlle A. E. Raats, André Verheem, Inne H. M. Borel Rinkes, Hugo J. G. Snippert, Madelon M. Maurice, Onno Kranenburg
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Organoids
Subjects:
organoids
colorectal cancer
BRAF
MAPK inhibition
drug resistance
linsitinib
Online Access:https://www.mdpi.com/2674-1172/4/2/14
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2674-1172/4/2/14

Similar Items